1-- Ryan, K.J. and Ray, C.G. (editors) (2004). Sherris Medical Microbiology, 4th ed., McGraw Hill, pp. 723–7.
2- Torda, A. (2001). Toxoplasmosis. Are cats really the source?" AustFamPhysician ,30 (8): 743–7.
3- Montoya, J., and Liesenfeld, O. (2004) .Toxoplasmosis. Lancet, 363 (9425): 1965–76.
4- Brito, A.F., Souza, L.C., Silva, A.V.,andLangoni, H. (2002). Epidemiological and serological aspects in canine toxoplasmosis in animals with nervous symptoms.Mem. Inst. Oswaldo Cruz., 97(1): 31-35.
5- Figueired, J., Silva, D.A., Cabral, D., and Mineo, J. (2001).Seroprevalence of Toxoplasma gondiiinfection in goat indirect heamagglutination, Immunoflurescence and immunoenzymatic tests in the region of unberlandia, Brazil. Mem.Inst. Oswaldo. Cruz, 96 (5) : 687 – 692.
6- Hiramoto, R.M., Borges, M.M., Galisteo, A.S., Meireles, L.R., Macre, M.S., Radem, H.F. (2001). Infectivity of cysts of the ME–49 Toxoplasma gondii strain in bovine milk and homemade chess. Rev. Saude. Publica., 35 (2) : 113 – 118.
7- Bagley, C.V. (2001). Infectious reproductive diseases of small ruminants. J. Infect. Dis. 31: 162 – 171.
8- Petersen ,E. and Schmidt D.R. (2003). Sulfadiazine and pyrimethamine in the postnatal treatment of congenital toxoplasmosis :what are the optins? Expert. Rev, Anti. Infect. Ther., 1(1):175-82.
9- Sharma, S.P., and Dubey, J.P. (1981). Quantitative survival of Toxoplasmagondiitachyzoites and bradyzoites in pepsin and in trypsin solutions. Am. J. Vet. Res., 42 : 128 – 130.
10- الحیالی، صباح سعید محمود احمد (2002) دراسـة تجریبیـة علـى عزلات المقوسات الکوندیة من المشیمات البشریة وتقییم کفاءة عـدد مـن المضادات الحیویـة فی علاجـها المستحدث فی الفئران/ محافظة نینوى، اطروحة دکتوراه/فلسفـة، کلیة العلوم قسم عـلوم الحیاة/ احیاء مجهریة، جامعة الموصل، العراق.
11- Dubey, J.P. (1997). Survival of Toxoplasma gondii tissue cysts in 0. 85 - 6% NaCl solution at 4 – 20º C. J. Parasitol., 83:946 -949.
12- Dubey, J.P. (1998). Re-examination of resistance of Toxoplasma gondiitachyzoites and bradyzoites to pepsin and trypsin digestion. Parasitology, 116:43-50.
13- Luna, L.G. (1968). Manual of histological staining methods. 3rd ed., McGraw-Hell Book Company, NewYork, p. 258.
15-Olgica, D. D.,and Vladimir, M. (2001). Murine model of drug-induced reactivation of Toxoplasma gondii.ActaProtozoologica., 40, 99–106.
16- Olgica, D. D., Vladimir M ., Aleksandra, N., Branko, B. and Jelica ,G. (2002). Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii . J. Antimicrob. Chemothe., 50: 981-987.
17- Derouin, F., Almadany, R., Chau, F., Rouveix, B.,andPocidalo, J.J. (1992). Synergistic activity of Azithromycin and pyrimethamine or sulfadiazine in acute experimental Toxoplasmosis. Antimicrob. Agents.Chemother., 997-1001.
18- Derouin, F. and Hayat, M.S .(2000). Anti-Toxoplasma activities of antiretriviral drugs and interactions with pyrimethamin and sulfadiazine in vitro.Antimicrob.Agents&Chemother.2575-77.
19- Romand, S., Pudney, M., and Derouin, F. (1993). In vitro and in vivo activities of the hydroxynaphthoquinone, sulfadiazine ,clrithromycin or minocycline against Toxoplasma gondii.Antimicrob. Agents and Chemother., p.2371-78.
20-McFadden, D.C., Camps, M. and Boothryod, C. (2001) .Resistance as a tool in the study of old and new drug targets in Toxoplasma. Drug Resistance Updates, 4:79-84.
21- Chamberland, S., Kirst, H.A. and Current, L. (1991). Comparative activity of macrolides against Toxoplasma gondii demonstrating utility of an in vitromicroassay .
22- Huskinson, M. J., Araujo, E. G. and Remington, J. S. (1991). Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J. Infect. Dis., 164:170 -171.
23- Derouin, F., Piketty, C., Chastang, C., Chau, F., Rouveix. B. and Pocidalo.J.J. (1991).Anti-Toxoplasma effects of dapsonealon and combind with pyrimethamin.Antimicrob. Agents and Chemother., 35:252-255.
24- Araujo, F.G. Slifer, T. and Remington, J. S. (1994). Rifabutin is active in murin models of toxoplasmosis. Antimicrob. Agents &Chemother., 38:570-575.
25- Stray, P.B (1999). Treatment of toxoplasmosis in pregnant mother and newborn child. Scand. J. Infect. Dis., 84:23-31.